![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Medical Research Center for Cancer Molecular Therapy and Department of Biochemistry, College of Medicine, Dong-A University, Busan, Korea (Y.-S.B., J.-Y.K.); Division of Molecular and Life Sciences, Pohang University of Science and Technology, Pohang, Korea (J.Y.S., Y.K., P.-G.S., S.H.R.); and Department of Pharmacology, University of Illinois, Chicago, Illinois (R.H., R.D.Y.)
Formyl peptide receptor (FPR) and formyl peptide receptor like 1 (FPRL1) play important roles in inflammation and immunity. Stimulation of FPR and FPRL1 initiates a cascade of signaling events, leading to activation of various phagocyte responses, including chemotaxis, superoxide generation, and exocytosis. Trp-Lys-Tyr-Met-Val-D-Met-NH2 (WKYMVm) is a synthetic peptide that binds to and activates FPR and FPRL1. To develop agonists that selectively activate phagocyte functions and therefore protect host from unwanted tissue damage, we generated various WKYMVm analogs and examined their effects on cellular responses in FPR- or FPRL1-expressing RBL-2H3 cells. Analogs with substitution at the third position such as WKGMVm, WKRMVm, as well as analogs with substitution at the sixth D-Met, selectively altered calcium mobilization in cells expressing FPRL1 but not in cells expressing FPR. Whereas binding of WKYMVm to FPR activates a broad spectrum of cellular signaling events, including phospholipase C-mediated intracellular calcium concentration ([Ca2+]i) mobilization and activation of extracellular signal-regulated kinase (ERK) and Akt, WKGMVm and WKRMVm could only activate ERK and Akt but did not induce [Ca2+]i mobilization. With respect to phagocyte functions, WKYMVm could induce both chemotaxis and exocytosis, but the two analogs WKGMVm and WKRMVm could only induce chemotaxis but not exocytosis. This study demonstrates that a major phagocyte chemoattractant receptor FPR may be activated differentially by distinct peptide ligands. Our results suggest that WKGMVm and WKRMVm may be useful model for further development of pharmacological agents that selectively activate FPR-mediated functions.
Address correspondence to: Dr. Sung Ho Ryu, Division of Molecular and Life Sciences, Pohang University of Science and Technology, Pohang, 790-784, Korea. E-mail: sungho{at}postech.ac.kr
This article has been cited by other articles:
|
|
 |
|
  F. D'Acquisto, A. Merghani, E. Lecona, G. Rosignoli, K. Raza, C. D. Buckley, R. J. Flower, and M. Perretti Annexin-1 modulates T-cell activation and differentiation Blood, February 1, 2007; 109(3): 1095 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Edwards, C. Bologa, S. M. Young, K. V. Balakin, E. R. Prossnitz, N. P. Savchuck, L. A. Sklar, and T. I. Oprea Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonists Mol. Pharmacol., November 1, 2005; 68(5): 1301 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Kang, H.-Y. Lee, M.-K. Kim, K. S. Park, Y. M. Park, J.-Y. Kwak, and Y.-S. Bae The Synthetic Peptide Trp-Lys-Tyr-Met-Val-D-Met Inhibits Human Monocyte-Derived Dendritic Cell Maturation via Formyl Peptide Receptor and Formyl Peptide Receptor-Like 2 J. Immunol., July 15, 2005; 175(2): 685 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gargiulo, I. Longanesi-Cattani, K. Bifulco, P. Franco, R. Raiola, P. Campiglia, P. Grieco, G. Peluso, M. P. Stoppelli, and M. V. Carriero Cross-talk between fMLP and Vitronectin Receptors Triggered by Urokinase Receptor-derived SRSRY Peptide J. Biol. Chem., July 1, 2005; 280(26): 25225 - 25232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Flower and M. Perretti Controlling inflammation: a fat chance? J. Exp. Med., March 7, 2005; 201(5): 671 - 674. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
